506606127 04/13/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT6652933

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
YONG HE	03/29/2021
XUECHAO XING	04/09/2021
GUOQIANG WANG	03/25/2021
RUICHAO SHEN	03/25/2021
BRETT GRANGER	04/06/2021
JIANG LONG	03/25/2021
YAT SUN OR	03/27/2021

RECEIVING PARTY DATA

Name:	ENANTA PHARMACEUTICALS, INC.
Street Address:	500 ARSENAL ST
City:	WATERTOWN
State/Country:	MASSACHUSETTS
Postal Code:	02472

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17155159

CORRESPONDENCE DATA

Fax Number:(978)251-3973Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent
using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.Phone:9782513509Email:edelmore@elmorepatents.com

Email:	cdelmore@elmorepatents.com
Correspondent Name:	ELMORE PATENT LAW GROUP P.C.
Address Line 1:	484 GROTON ROAD
Address Line 4:	WESTFORD, MASSACHUSETTS 01886

ATTORNEY DOCKET NUMBER:	4014.1350 US3
NAME OF SUBMITTER:	EDGAR W. HARLAN, REG NO. 42632
SIGNATURE:	/EDGAR W. HARLAN/
DATE SIGNED:	04/13/2021

Total Attachments: 4 source=4014.1350 US3 Executed Assignment#page1.tif source=4014.1350 US3 Executed Assignment#page2.tif source=4014.1350 US3 Executed Assignment#page3.tif source=4014.1350 US3 Executed Assignment#page4.tif

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown, MA 02472

(hereinafter referred to "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS

as set forth in the following Patent Application(s):

United States Patent Application No. 17/155,159, filed January 22, 2021

as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified applications and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or

PATENT REEL: 055899 FRAME: 0925 inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of Elmore Patent Law Group, P.C. the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of Elmore Patent Law Group, P.C. do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel. and the second se at and

InventorYÓNG HE	Date2/202/
Witness Name Yanchun Wang	Date3129/2021
InventorXUECHAO XING	Date <i>4/9/2024</i>
Witness Name Yanchun Wang	Date 49/2021
Inventor GUOQIANG WANG	Date3/25/2021
Witness Name_ <u>Yanchun</u>	Date3) 2ぶ つらこ)
Inventor	Date3/25/2021
Witness Name_Janchun Wang	Date <u>31_251_2021</u>

Assignment Serial No. 17/155,159 First Inventor Yong He Title: Heterocyclic Compounds as Anti-Viral Agents Docket No. 4014.1350 US3

Inventor_	Byth yourfu
	BRETT GRANGER

JIANG LONG

Date 4/6/2021

Date 46 2021

Yonehan Wang_____

Date

Date_____

Date_____

Inventor_____

Witness Name_____

Witness Name____

Inventor_____YAT SUN OR

Date_____ Witness Name_____

IN TESTIMONY WHEREOF, I, on behalf of and duly authorized by the ASSIGNEE, have executed this Assignment.

ENANTA PHARMACEUTICALS, INC.

By:

Name: Nathaniel S. Gardiner

Title: Senior Vice President and General Counsel

Assignment Serial No. 17/155,159 First Inventor Yong He Title: Heterocyclic Compounds as Anti-Viral Agents Docket No. 4014.1350 US3

Inventor BRETT GRANGER	Date
Witness Name	Date
Inventor	Date3)25 202
Witness Name Yanghun Wang	Date <u>3 25 2027</u>
InventorYAT SUN OR	Date 3/27/2024
Witness Name_Joinchun Warg	Date3/ ≥ 7 / 2-02/

IN TESTIMONY WHEREOF, I, on behalf of and duly authorized by the ASSIGNEE, have executed this Assignment.

ENANTA PHARMACEUTICALS, INC.

8v

Name: Nathaniel S. Gardiner

Title: Senior Vice President and General Counsel

÷

 $\phi^{(i)}$